Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Extent of Intracellular Accumulation of Bilirubin Determines Its Anti- or Pro-Oxidant Effect

A. Bianco, A. Dvořák, N. Capková, C. Gironde, C. Tiribelli, C. Furger, L. Vitek, C. Bellarosa

. 2020 ; 21 (21) : . [pub] 20201030

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011974

Grantová podpora
NW18-07-00342 Czech Ministry of Health
RVO-VFN64165/2020 Czech Ministry of Health

BACKGROUND: Severe hyperbilirubinemia can cause permanent neurological damage in particular in neonates, whereas mildly elevated serum bilirubin protects from various oxidative stress-mediated diseases. The present work aimed to establish the intracellular unconjugated bilirubin concentrations (iUCB) thresholds differentiating between anti- and pro-oxidant effects. METHODS: Hepatic (HepG2), heart endothelial (H5V), kidney tubular (HK2) and neuronal (SH-SY5Y) cell lines were exposed to increasing concentration of bilirubin. iUCB, cytotoxicity, intracellular reactive oxygen species (ROS) concentrations, and antioxidant capacity (50% efficacy concentration (EC50)) were determined. RESULTS: Exposure of SH-SY5Y to UCB concentration > 3.6 µM (iUCB of 25 ng/mg) and >15 µM in H5V and HK2 cells (iUCB of 40 ng/mg) increased intracellular ROS production (p < 0.05). EC50 of the antioxidant activity was 21 µM (iUCB between 5.4 and 21 ng/mg) in HepG2 cells, 0.68 µM (iUCB between 3.3 and 7.5 ng/mg) in SH-SY5Y cells, 2.4 µM (iUCB between 3 and 6.7 ng/mg) in HK2 cells, and 4 µM (iUCB between 4.7 and 7.5 ng/mg) in H5V cells. CONCLUSIONS: In all the cell lines studied, iUCB of around 7 ng/mg protein had antioxidant activities, while iUCB > 25 ng/mg protein resulted in a prooxidant and cytotoxic effects. UCB metabolism was found to be cell-specific resulting in different iUCB.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011974
003      
CZ-PrNML
005      
20210507102739.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21218101 $2 doi
035    __
$a (PubMed)33143041
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bianco, Annalisa $u Italian Liver Foundation (FIF), Bldg Q-AREA Science Park Basovizza, SS14 Km 163,5, 34149 Trieste, Italy $u Department of Life Sciences, University of Trieste, 34127 Trieste, Italy
245    14
$a The Extent of Intracellular Accumulation of Bilirubin Determines Its Anti- or Pro-Oxidant Effect / $c A. Bianco, A. Dvořák, N. Capková, C. Gironde, C. Tiribelli, C. Furger, L. Vitek, C. Bellarosa
520    9_
$a BACKGROUND: Severe hyperbilirubinemia can cause permanent neurological damage in particular in neonates, whereas mildly elevated serum bilirubin protects from various oxidative stress-mediated diseases. The present work aimed to establish the intracellular unconjugated bilirubin concentrations (iUCB) thresholds differentiating between anti- and pro-oxidant effects. METHODS: Hepatic (HepG2), heart endothelial (H5V), kidney tubular (HK2) and neuronal (SH-SY5Y) cell lines were exposed to increasing concentration of bilirubin. iUCB, cytotoxicity, intracellular reactive oxygen species (ROS) concentrations, and antioxidant capacity (50% efficacy concentration (EC50)) were determined. RESULTS: Exposure of SH-SY5Y to UCB concentration > 3.6 µM (iUCB of 25 ng/mg) and >15 µM in H5V and HK2 cells (iUCB of 40 ng/mg) increased intracellular ROS production (p < 0.05). EC50 of the antioxidant activity was 21 µM (iUCB between 5.4 and 21 ng/mg) in HepG2 cells, 0.68 µM (iUCB between 3.3 and 7.5 ng/mg) in SH-SY5Y cells, 2.4 µM (iUCB between 3 and 6.7 ng/mg) in HK2 cells, and 4 µM (iUCB between 4.7 and 7.5 ng/mg) in H5V cells. CONCLUSIONS: In all the cell lines studied, iUCB of around 7 ng/mg protein had antioxidant activities, while iUCB > 25 ng/mg protein resulted in a prooxidant and cytotoxic effects. UCB metabolism was found to be cell-specific resulting in different iUCB.
650    _2
$a antioxidancia $x farmakologie $7 D000975
650    _2
$a bilirubin $x farmakologie $7 D001663
650    _2
$a hepatocelulární karcinom $x farmakoterapie $x metabolismus $x patologie $7 D006528
650    _2
$a lidé $7 D006801
650    _2
$a hyperbilirubinemie $x patofyziologie $7 D006932
650    _2
$a nádory jater $x farmakoterapie $x metabolismus $x patologie $7 D008113
650    _2
$a neuroblastom $x farmakoterapie $x metabolismus $x patologie $7 D009447
650    _2
$a oxidancia $x farmakologie $7 D016877
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Aleš $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and 1st Faculty of Medicine, Charles University, 121 08 Prague 2, Czech Republic
700    1_
$a Capková, Nikola $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and 1st Faculty of Medicine, Charles University, 121 08 Prague 2, Czech Republic
700    1_
$a Gironde, Camille $u AOP/MH2F Team, LAAS-CNRS, 7 avenue de l'Europe, 31400 Toulouse, France
700    1_
$a Tiribelli, Claudio $u Italian Liver Foundation (FIF), Bldg Q-AREA Science Park Basovizza, SS14 Km 163,5, 34149 Trieste, Italy
700    1_
$a Furger, Christophe $u AOP/MH2F Team, LAAS-CNRS, 7 avenue de l'Europe, 31400 Toulouse, France
700    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and 1st Faculty of Medicine, Charles University, 121 08 Prague 2, Czech Republic $u 4th Department of Internal Medicine, Faculty General Hospital and 1st Faculty of Medicine, Charles University, 121 08 Prague 2, Czech Republic
700    1_
$a Bellarosa, Cristina $u Italian Liver Foundation (FIF), Bldg Q-AREA Science Park Basovizza, SS14 Km 163,5, 34149 Trieste, Italy
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 21 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33143041 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102739 $b ABA008
999    __
$a ok $b bmc $g 1650367 $s 1132353
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 21 $e 20201030 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NW18-07-00342 $p Czech Ministry of Health
GRA    __
$a RVO-VFN64165/2020 $p Czech Ministry of Health
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...